RaySearch Laboratories ABRSLBF +0.81%92 PEG Ratio is 1.12 as of Jul. 03, 2026, which is 77% below its 10-year median of 4.87. GuruFocus rates RSLBF with a GF Score™ of 92/100 and a GF Value™ of $20.80 (Fairly Valued). The stock has 2 warning signs investors should review. Among 225 Healthcare Providers & Services companies, RaySearch Laboratories AB ranks better than 53.33% on this metric.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for RaySearch Laboratories AB's PEG Ratio or its related term are showing as below:
RSLBF'
s PEG Ratio Range Over the Past 10 Years
Min: 1.24 Med: 4.87 Max: 10.79
Current: 1.24
During the past 13 years, RaySearch Laboratories AB's highest PEG Ratio was 10.79. The lowest was 1.24. And the median was 4.87.
RSLBF's PEG Ratio is ranked better than 53.33% of 225
companies
in the Healthcare Providers & Services industry
Industry Median: 1.41
vs RSLBF: 1.24
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
RaySearch Laboratories AB (OTCPK:RSLBF) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
RaySearch Laboratories AB PEG Ratio Related Terms
RaySearch Laboratories AB PEG Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, RaySearch Laboratories AB's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RaySearch Laboratories AB PEG Ratio vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, RaySearch Laboratories AB's PEG Ratio distribution charts can be found below:
* The bar in red indicates where RaySearch Laboratories AB's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
RaySearch Laboratories AB (RSLBF) has a PEG Ratio of 1.12 as of Jul. 03, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on RaySearch Laboratories AB and its competitors. This is 77% below median its historical median of 4.87. Over the past decade, RaySearch Laboratories AB's PEG Ratio has ranged from 1.24 to 10.79. According to the industry distribution chart, RaySearch Laboratories AB ranks #105 out of 225 companies in the Healthcare Providers & Services industry, placing it in the top 46.7%.
Is RaySearch Laboratories AB's PEG Ratio too high?
RaySearch Laboratories AB's current PEG Ratio of 1.12 is 77% below median its 10-year median of 4.87. Over the past 10 years, this metric has ranged from a low of 1.24 to a high of 10.79. The Healthcare Providers & Services industry median PEG Ratio is 1.41. RaySearch Laboratories AB's value of 1.12 is 20.6% below this industry median. Based on the distribution chart, RaySearch Laboratories AB ranks #105 out of 225 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, RaySearch Laboratories AB has a GF Score™ of 92/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does RaySearch Laboratories AB's PEG Ratio compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, RaySearch Laboratories AB ranks #105 out of 225 companies for PEG Ratio. This puts RaySearch Laboratories AB in the upper half of its industry. The industry median PEG Ratio is 1.41. RaySearch Laboratories AB's value of 1.12 is 20.6% below this benchmark. Historically, RaySearch Laboratories AB's own PEG Ratio has ranged from 1.24 to 10.79 over the past decade. While the company's 10-year median is 4.87 vs. the industry median of 1.41, RaySearch Laboratories AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Healthcare Providers & Services company?
The median PEG Ratio among Healthcare Providers & Services companies is 1.41, based on 225 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. RaySearch Laboratories AB's current PEG Ratio of 1.12 is 20.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on RaySearch Laboratories AB and its competitors. For the Healthcare Providers & Services industry, the median PEG Ratio is 1.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RaySearch Laboratories AB's current PEG Ratio is 1.12, which is 77% below median its own 10-year median of 4.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RaySearch Laboratories AB stock overvalued right now?
Based on GuruFocus' analysis, RaySearch Laboratories AB (RSLBF) is currently considered Fairly Valued. The stock's GF Value™ is $20.80, compared to a current price of $21.17 — trading 1.8% above its estimated fair value. The current PEG Ratio is 1.12, which is 77% below median its 10-year median of 4.87 and 20.6% below the Healthcare Providers & Services industry median of 1.41. RaySearch Laboratories AB's overall GF Score™ is 92/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For RaySearch Laboratories AB (RSLBF), the current PEG Ratio is 1.12 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is RaySearch Laboratories AB (RSLBF) Overvalued in 2026?
Based on GuruFocus' analysis, RaySearch Laboratories AB stock appears to be overvalued.
The current stock price of $21.17 is trading 1.8% above its estimated GF Value™ of $20.80.
GuruFocus considers RaySearch Laboratories AB to be Fairly Valued.
Key valuation signals for RSLBF:
PEG Ratio: 1.12 (77% below median its 10-year median of 4.87)
GF Value™: $20.80 vs. price of $21.17 (1.8% above fair value)
Industry Position: 20.6% below the Healthcare Providers & Services median (#105 of 225)
No single metric tells the full story. See the RSLBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
RaySearch Laboratories AB is a Sweden-based medical technology company. The company develops software solutions for improved cancer treatment. The company develops and markets the RayStation treatment planning system and RayCare oncology information system to clinics all over the world and distributes products through licensing agreements with medical technology companies. Its geographic segments consist of the Americas, Asia-Pacific & Middle East, Europe, and the rest of world.
92GF Score
Get the complete analysis for RSLBF
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RSLBF has been successfully added to your 
